Revenue
198 thousand iso4217-usd
2017 Q4 · iso4217-usd
Fundies. English
BIOLARGO, INC.
EDGAR158 filing records in this dataset, filed from 1996-08-20 to 2026-08-14. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating margin
-755.7%
2017 Q4 · %
Operating cash flow
-1.21 million iso4217-usd
2017 Q4 · iso4217-usd
- Cash and cash equivalents
- 2.19 million USD Source
Exact value
2188000 USD
- Long-term debt including current maturities
- 2.08 million USD Source
Exact value
2079000 USD
- Shares outstanding
- 293 million shares Source
Exact value
292945747 shares
Reported share-count change
5.20% · 14.5 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-14.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2023-12-31
- Operating income: 7 of 11 periods available· newest 2025-12-31
- net income: No compatible figures in this window
- Operating cash flow: 7 of 11 periods available· newest 2025-12-31
- Capital expenditure: 1 of 11 periods available· newest 2017-12-31
- Total assets: 7 of 11 periods available· newest 2025-12-31
- Total liabilities: 7 of 11 periods available· newest 2025-12-31
- Current assets: 7 of 11 periods available· newest 2025-12-31
- Current liabilities: 7 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 2 of 11 periods available· newest 2025-12-31
- Shares outstanding: 2 of 11 periods available· newest 2023-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Operating cash flow
−USD 5.09 millionPrior period
−USD 3.21 million
–
Current period
−USD 8.3 million
–
Exact inputs and evidence
-8297000 − -3206000 = -5091000 USD
-3206000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-8297000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Net income, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2023 2023-01-01 – 2023-12-31
- Revenue USD 12.23 million 100% of revenue
- Cost of revenue USD 6.08 million 50% of revenue
- Operating expenses USD 10.73 million 88% of revenue
- Operating income −USD 4.58 million −37% of revenue
- Tax, interest and other Derived Unavailable An input is unavailable.
- Net income Unavailable An input is unavailable.
Cash
- Operating cash flow −USD 2.37 million −19% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2015 Not shown: operating income or net income is not reported.
- 2023 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | 127582 | 4309063 Derived | -4181481 | Unavailable | Unavailable | Unavailable | Source
|
| 2023 2023-01-01 – 2023-12-31 | 12230000 | 16810000 Derived | -4580000 | Unavailable | Unavailable | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 12.2M 2023
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Revenue | 127582 |
|
| 2023 | Revenue | 12230000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Year over year | No prior comparable period |
|
| 2023 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -37.4% 2023
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Operating margin | -3,277.5% |
|
| 2023 | Operating margin | -37.4% |
|
| 2015-12-31 | Net margin | Not reported |
|
| 2023-12-31 | Net margin | Not reported |
|
| 2015 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -2.4M 2023
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Operating cash flow | -1883342 |
|
| 2023 | Operating cash flow | -2365000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Free cash flow | Unavailable |
|
| 2023 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
48.8% 2023
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Liabilities / assets | 40.3% |
|
| 2023 | Liabilities / assets | 48.8% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
2.35× 2023
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Current assets / current liabilities | 4.11× |
|
| 2023 | Current assets / current liabilities | 2.35× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | Unavailable Not reported for this period. | −USD 1.88 million Exact valueExact value: -1883342 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | Unavailable Not reported for this period. | −USD 4.15 million Exact valueExact value: -4154000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | Unavailable Not reported for this period. | −USD 3.94 million Exact valueExact value: -3937000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | Unavailable Not reported for this period. | −USD 2.76 million Exact valueExact value: -2762000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | Unavailable Not reported for this period. | −USD 2.37 million Exact valueExact value: -2365000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | Unavailable Not reported for this period. | −USD 3.21 million Exact valueExact value: -3206000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | Unavailable Not reported for this period. | −USD 8.3 million Exact valueExact value: -8297000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
158 filings · 4,389 latest values · 4,389 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000880242, 880242, BLGO, blgo, edgar:880242
Also known as BIOLARGO, INC., LATIN AMERICAN CASINOS INC, NUWAY ENERGY INC, NUWAY MEDICAL INC